Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Revelation Biosciences (NASDAQ: REVB) announced that its Board Compensation Committee approved three inducement equity grants on July 15, 2026, totaling 108,000 restricted stock units (RSUs) for three newly hired non-executive employees. The RSUs, issued under the 2026 Equity Inducement Plan, are intended as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in equal quarterly installments over two years, beginning on October 15, 2026 and ending on July 15, 2028, contingent on continued employment or service. According to Revelation Biosciences, the company is a clinical-stage life sciences firm developing inflammation-rebalancing therapies using its proprietary formulation, Gemini, across multiple acute and chronic indications.

Positive

• 108,000 RSUs granted to support new non-executive hires
• Two-year quarterly vesting structure aligns employee incentives with retention

Negative

• Equity awards covering 108,000 shares add incremental potential dilution for shareholders

Market Context

REVB recorded a -0.46% 24-hour reaction after a prior advisory-board expansion. Against that mixed h...

Analysis

REVB recorded a -0.46% 24-hour reaction after a prior advisory-board expansion. Against that mixed history, the employee grants add a defined vesting schedule; the active S-3/A resale registration remains relevant context.

Key Figures

Inducement grants: 3 grants Restricted stock units: 108,000 RSUs Common shares covered: 108,000 shares +4 more

7 metrics

Inducement grants 3 grants Approved July 15, 2026

Restricted stock units 108,000 RSUs Granted to three newly hired non-executive employees

Common shares covered 108,000 shares Shares underlying the RSUs

Vesting period Two years Subject to continued employment or service

Vesting cadence Equal quarterly installments RSU vesting schedule

First vesting date October 15, 2026 First installment

Final vesting date July 15, 2028 Final installment

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Advisory board expansion	Positive	-0.5%	Added internationally recognized intensive care and nephrology leaders to the AKI advisory board.
May 11	Corporate update	Positive	+1.9%	Outlined FDA-supported development plans, cash resources, funding outlook, and reduced annual net loss.
May 07	Quarterly earnings	Negative	-5.9%	Reported quarterly net loss, operating cash usage, and resources funding operations through Q1 2027.
Apr 06	Advisory board formation	Positive	-7.2%	Formed an AKI advisory board to guide the upcoming Phase 2/3 clinical trial.
Mar 30	Clinical study data	Positive	+5.3%	Reported durable cytokine normalization and restored immunocompetence in CKD patient samples.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The five-event record was mixed: three reactions aligned with the event assessment and two diverged, including negative reactions to two positive management updates.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4), acute kidney injury, hyperinflammation

4 terms

restricted stock units financial

"three inducement grants totaling 108,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

acute kidney injury medical

"Gemini as a treatment for acute kidney injury"

A sudden decline in how well the kidneys remove waste and balance fluids, often developing over hours or days; think of it like an engine that abruptly loses power and can’t filter efficiently. It matters to investors because it can drive higher medical costs, alter clinical trial results, trigger regulatory scrutiny, lead to drug label changes or recalls, and affect revenue and liability for healthcare and life sciences companies.

hyperinflammation medical

"reduce hyperinflammation and infection associated with severe burn"

An excessive, uncontrolled immune response that causes collateral damage to the body’s own tissues, like a fire brigade spraying so much water that it floods a building while putting out a blaze. Investors should care because hyperinflammation can drive severe illness, change clinical trial outcomes, increase treatment costs, create demand for new drugs or diagnostics, and influence regulatory decisions and market potential for therapies targeting inflammatory conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that on July 15, 2026, the Compensation Committee of Revelation's Board of Directors approved three inducement grants totaling 108,000 restricted stock units ("RSUs") covering 108,000 shares of the Company's common stock to three newly hired non-executive employees. The inducement grants were granted pursuant to the Revelation Biosciences, Inc. 2026 Equity Inducement Plan ("2026 Inducement Plan"). The awards were granted as a material inducement to the employees' acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over two years in equal quarterly installments, with the first installment vesting on October 15, 2026, and the final installment vesting on July 15, 2028, subject to the employee's continued employment or service with the Company through the vesting dates. The RSUs are subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of the restricted stock unit agreement covering the grants.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.

For more information, please visit www.RevBiosciences.com.

Company Contacts:

Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences Inc.

View the original press release on ACCESS Newswire

FAQ

What inducement equity grants did Revelation Biosciences (REVB) announce on July 21, 2026?

Revelation Biosciences announced three inducement grants totaling 108,000 RSUs for newly hired non-executive employees. According to Revelation Biosciences, these RSUs were approved on July 15, 2026 under the company’s 2026 Equity Inducement Plan.

How many Revelation Biosciences (REVB) shares are covered by the July 2026 inducement RSU grants?

The inducement awards cover 108,000 shares of Revelation Biosciences common stock through restricted stock units. According to Revelation Biosciences, these RSUs were granted to three newly hired non-executive employees as a material inducement to accept employment.

What is the vesting schedule for the 108,000 RSUs granted by Revelation Biosciences (REVB)?

The 108,000 RSUs vest over two years in equal quarterly installments. According to Revelation Biosciences, vesting begins on October 15, 2026 and ends on July 15, 2028, subject to continued employment or service with the company.

Why did Revelation Biosciences (REVB) use Nasdaq Listing Rule 5635(c)(4) for these RSU grants?

Revelation Biosciences granted the RSUs as a material inducement to the employees’ acceptance of employment. According to Revelation Biosciences, the awards were made under Nasdaq Listing Rule 5635(c)(4), which permits inducement equity grants outside shareholder-approved plans.

Under which equity plan were the July 2026 Revelation Biosciences (REVB) inducement RSUs granted?

The inducement RSUs were granted under the Revelation Biosciences 2026 Equity Inducement Plan. According to Revelation Biosciences, the RSUs are also governed by the applicable restricted stock unit agreements that outline specific terms and conditions for each grant.

What clinical programs is Revelation Biosciences (REVB) pursuing with its Gemini formulation?

Revelation Biosciences is evaluating its Gemini formulation across several inflammation-related indications. According to Revelation Biosciences, programs include treatment for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and reducing hyperinflammation and infection in patients with severe burns.